In the global pharmaceutical industry, there were 52 private equity deals announced in Q3 2024, worth a total value of $7.1bn, according to GlobalData's Deals Database. The $1.5bn institutional buy-out (ibo) PetIQ by Bansk Group was the industry's largest disclosed deal. A thorough analysis of the disruptive themes and the Private Equity deal activity are included in GlobalData's Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, private equity deal activity increased by 29% in Q3 2024 compared with the previous quarter's total of $5.5bn and rose by 21% as compared to Q3 2023. Related deal volume decreased by 22% in Q3 2024 versus the previous quarter and was 10% lower than in Q3 2023.
Notably, foreign direct investments (fdi)-related deals accounted for a 39% share of the global pharmaceutical industry’s private equity deal activity in Q3 2024, up 17% over the previous quarter.
The top-ranked financial advisors supporting these private equity deals in 9M 2024 were Houlihan Lokey; Jefferies Financial Group; Rothschild & Co with 6, 5, 5 deals respectively.
The top-ranked legal advisors supporting these private equity deals in 9M 2024 were Kirkland & Ellis; Ropes & Gray; McDermott Will & Emery with 15, 9, 8 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2024 – Strategic Intelligence, buy the report here.
